Screener
Nurix Therapeutics, Inc. NRIX Contract Liabilities, Non-Current
Contract Liabilities, Non-Current at other companies
Other financials
Where this comes from
Reported directly by Nurix Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.
The source filing: Nurix Therapeutics, Inc.’s 10-Q, filed July 9, 2026.
- Filed
- Jul 9, 2026, 4:12 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001549595-26-000040
| Line item | May 31,2026 | November 30,2025 |
|---|---|---|
| Deferred revenue, current | 13,324 | 17,580 |
| Total current liabilities | 72,020 | 86,471 |
| Operating lease liabilities, net of current portion | 54,922 | 52,906 |
| Deferred revenue, net of current portion | 5,971 | 10,011 |
| Total liabilities | 132,913 | 149,388 |
| Commitments and contingencies (Note 6) | ||
| Stockholdersʼ equity: | ||
| Preferred stock, $0.001 par value— 10,000,000 shares authorized as of May 31, 2026 and November 30, 2025; no shares issued and outstanding as of May 31, 2026 and November 30, 2025 | — | — |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Nurix Therapeutics, Inc.'s contract liabilities, non-current?
- Nurix Therapeutics, Inc. (NRIX) reported contract liabilities, non-current of $5.97M in Q1 2026.
- How has Nurix Therapeutics, Inc.'s contract liabilities, non-current changed year-over-year?
- Nurix Therapeutics, Inc.'s contract liabilities, non-current decreased by 72.4% year-over-year, from $21.64M to $5.97M.
- What is the long-term trend for Nurix Therapeutics, Inc.'s contract liabilities, non-current?
- Over 5 years (2020 to 2025), Nurix Therapeutics, Inc.'s contract liabilities, non-current has grown at a -30.3% compound annual growth rate (CAGR), from $60.69M to $10.01M.
Ask your AI about Nurix Therapeutics, Inc.'s contract liabilities, non-current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude